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Abstract
Background: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare neurodegenerative disorder in humans included in
the group of Transmissible Spongiform Encephalopathies or prion diseases. The vast majority of sCJD cases are
molecularly classified according to the abnormal prion protein (PrP
Sc) conformations along with polymorphism of
codon 129 of the PRNP gene. Recently, a novel human disease, termed “protease-sensitive prionopathy”, has been
described. This disease shows a distinct clinical and neuropathological phenotype and it is associated to an
abnormal prion protein more sensitive to protease digestion.
Case presentation: We report the case of a 75-year-old-man who developed a clinical course and presented
pathologic lesions compatible with sporadic Creutzfeldt-Jakob disease, and biochemical findings reminiscent of
“protease-sensitive prionopathy”. Neuropathological examinations revealed spongiform change mainly affecting the
cerebral cortex, putamen/globus pallidus and thalamus, accompanied by mild astrocytosis and microgliosis, with
slight involvement of the cerebellum. Confluent vacuoles were absent. Diffuse synaptic PrP deposits in these
regions were largely removed following proteinase treatment. PrP deposition, as revealed with 3F4 and 1E4
antibodies, was markedly sensitive to pre-treatment with proteinase K. Molecular analysis of PrP
Sc showed an
abnormal prion protein more sensitive to proteinase K digestion, with a five-band pattern of 28, 24, 21, 19, and
16 kDa, and three aglycosylated isoforms of 19, 16 and 6 kDa. This PrP
Sc was estimated to be 80% susceptible to
digestion while the pathogenic prion protein associated with classical forms of sporadic Creutzfeldt-Jakob disease
were only 2% (type VV2) and 23% (type MM1) susceptible. No mutations in the PRNP gene were found and
genotype for codon 129 was heterozygous methionine/valine.
Conclusions: A novel form of human disease with abnormal prion protein sensitive to protease and MV at codon
129 was described. Although clinical signs were compatible with sporadic Creutzfeldt-Jakob disease, the molecular
subtype with the abnormal prion protein isoforms showing enhanced protease sensitivity was reminiscent of the
“protease-sensitive prionopathy”. It remains to be established whether the differences found between the latter
and this case are due to the polymorphism at codon 129. Different degrees of proteinase K susceptibility were
easily determined with the chemical polymer detection system which could help to detect proteinase-susceptible
pathologic prion protein in diseases other than the classical ones.
Background
Sporadic Creutzfeldt-Jakob disease (sCJD) is a fatal neuro-
degenerative disorder which constitutes the most common
form of human Transmissible Spongiform Encephalopathy
(TSE) occurring at a rate of 1-1.5 cases per million of the
population per annum [1]. Clinical features may vary but
classic sCJD cases present a rapidly progressive dementia
accompanied by focal neurological signs that progress
to akinetic mutism and death within 4-6 months [2,3].
Neuropathologic hallmarks are neuronal loss, spongiosis
and reactive gliosis, which are variable in nature, severity
and location [4,5]. Two protease resistant PrP
Sc types have
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three-band pattern: diglycosylated, monoglycosylated and
aglycosylated. Type 1 is characterised by an aglycosylated
isoform of 21 kDa whereas type 2 isoform is 19 kDa in
size [6]. Few sCJD cases have been described with PrP
Sc
conformations different from type 1 and type 2 after
proteinase-K (PK) digestion [7-10]. Two of them were
characterised by the absence of the diglycosylated isoform
[7,8], while a unique PrP
Sc resistant fragment of 6 kDa
size was observed in another case [9]. More recently, a
novel human disease, defined by the authors as “protease-
sensitive prionopathy” (PSPr) has been described. It
showed a distinct clinical and neuropathological pheno-
type and a more sensitive to PK digestion PrP
Sc [10].
Patients presented behavioural and psychiatric manifesta-
tions and longer duration of the disease and all of them
were valine homozygous. Histopathologically, minimal
spongiform degeneration with larger vacuoles than in typi-
cal sCJD as well as minimal astrogliosis were described.
This lesion profile mainly affected the cerebral neocortex,
basal ganglia and thalamus. Abnormal PrP was less resis-
tant to PK digestion and it showed a ladder-like pattern
on Western blot, with PrP fragments ranging from 29 to
6 kDa, all detected with Mab 1E4.
Case presentation
Clinical findings
A 74-year-old man presented to his general practitioner in
August 2006 complaining of memory loss and was then
referred to the neurologist. He showed a rapid global cog-
nitive decline associated with aggressiveness, bizarre beha-
viour and language loss. This was accompanied by severe
anomia, disinhibition and a score of 10/30 on MMSE.
There were no focal signs, myoclonus or ataxia. The clini-
cal deterioration was very rapid and by December 2006 he
was in an akinetic-mutism-like syndrome with abnormal
posturing. Two cranial magnetic resonance imaging
(MRI), in October and December 2006, including T1, T2,
FLAIR and DWI sequences, showed moderate signs of
brain atrophy but no increase in abnormal cortical or
basal ganglia signal. Electroencephalogram (EEG) was
non-diagnostic and protein 14-3-3 level in the cerebrosp-
inal fluid (CSF) was normal. The patient died in March
2007. Family history of dementia included an 80-year-old
brother diagnosed with probable Alzheimer disease.
Genetic findings
No mutations were found in the open reading frame after
sequencing the prion protein gene (PRNP). A heterozy-
gosis methionine valine (MV) was observed in codon 129.
Neuropathology
Moderate-to-mild spongiform change was present in the
neocortex, putamen/globus pallidus and thalamus, with
the lesions being more evident in the putamen and frontal
cortex (Figure 1A and 1B). Confluent vacuoles were not
found in any region. Except for a few focal vacuoles in the
deeper molecular layer, the cerebellar cortex was other-
wise unremarkable (Figure 1C). Neurons were largely
preserved in the cerebral cortex and basal ganglia although
focal astrogliosis was seldom observed (Figure 1D). Mild-
to-moderate microgliosis was present in the cerebral
cortex and basal ganglia, and subcortical white matter,
respectively (Figure 1E and 1F). Immunostaining of PrP
without proteinase K pre-treatment showed strong stain-
ing characterised by fine punctate deposits (synaptic-like)
and irregular granular, often confluent, deposits that could
be categorised as diffuse synaptic (Figure 1G and 1H).
Perineuronal and cerebellar plaque-like deposits, kuru
plaques and florid plaques were absent. Following PK
treatment, the vast majority of staining disappeared, except
a few granular PrP PK-resistant deposits (Figure 1G
and 1I). The cerebellum showed a discrete PrP synaptic-
like pattern in the molecular and granular layers which
vanished after PK pre-treatment. Sensitivity to PK
pre-treatment was best visualized in consecutive sections
with and without pre-treatment with PK (Figure 2). Paral-
lel sections stained with the 3F4 antibody showed marked
reduction of PrP immunoreactivity, as evaluated by densi-
tometry, involving 70-80% of the total PrP in tissue
sections. This was further confirmed by incubating tissue
sections with the 1E4 antibody, and comparing the PrP
immunohistochemical pattern of one sCJD MV1 case with
the proband. As shown in Figure 3, 3F4 and 1E4 synaptic
PrP immunoreactivity in the common MV1 case showed
resistant PrP immunoreactivity (Figure 3A-D). In contrast,
3F4 and 1E4 immunoreactivity was practically abolished
after PK pre-treatment in the proband (Figure 3E-H).
In addition to these changes, neurofibrillary tangles
and pre-tangles, as well as granules (grains), were pre-
sent in the entorhinal and perirhinal cortices, subicu-
lum and CA1 and CA3 regions of the hippocampus. A
few pre-tangles and grains were also seen in the amyg-
dala. These changes were accompanied by a few hyper-
phosphorylated tau deposits in neurons of the dentate
gyrus, coiled bodies in the white matter of the tem-
poral lobe, and peri-ventricular astrocytes. Scattered
aB-crystallin-immunoreactive ballooned neurons were
present in the entorhinal cortex and amygdala. Tau
pathology was consistent with Alzheimer disease stage
III and argyrophilic grain disease stage 3. Amyloid pla-
ques and a-synuclein inclusions were absent. No
abnormalities were found with anti-TDP-43 antibodies.
Biochemical analysis
Standard PrP Western-blot procedure (10% brain homo-
genate and final PK concentration of 440 μg/ml) failed
to detect PrP
Sc. Increasing the volume loaded into the
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Page 2 of 10gel from 5 to 10 μl yielded an extremely weak signal
corresponding to 24 and 19 kDa under saturating film
exposure times (Figure 4A). Decreasing PK concentra-
tions (440, 100 and 50 μg/ml) showed an increase in the
PrP
Sc signal, which was suggestive of a PK-sensitive
prion protein (Figure 4B). Even then, only two bands of
24 and 19 kDa were visible. After increasing the brain
homogenate percentage to 20%, the same two-band pat-
tern was obtained.
Using the TeSeE® kit, characterised by softer PK diges-
tion conditions followed by steps of purification and
concentration of the protein and staining with Sha31
M a b ,t h ep r e s e n c eo ft w ou n e x p e c t e db a n d so f2 1a n d
16 kDa was revealed (Figure 5A). This band profile was
observed in all the brain regions and it constituted a
striking result, since their molecular weight was different
from that previously detected with Mab 3F4 and 6H4.
Performing a combination of digestion, purification and
concentration of the sample according to TeSeE® kit
recommendations, along with detection using 3F4 and
6H4, yielded a novel pattern. Not only the previous
bands of 24, 21, 19 and 16 kDa were present in each of
the samples, but also a very weak band of 28 kDa and a
fragment of approximately 6kDa size were observed in
some brain regions (Figure 5B). Furthermore, differences
of signal intensity were obtained with 3F4 and 6H4 anti-
bodies suggesting differential affinity for PrP
Sc which
could be interpreted as a different protein conformation
in which the 3F4-binding epitope was more exposed
than the 6H4 one.
Figure 1 Main neuropathological findings. A: Mild spongiform change in the frontal cortex; B: Mild spongiform change in the putamen/
globus pallidus characterised by predominance of large vacuoles; C: A few small vacuoles in the vicinity of a Purkinje cell; D: Focal astrocytosis
in the cerebral cortex; E and F: Microgliosis with globular reactive microglia in the cerebral cortex and subcortical white matter, respectively; G:
PrP immunostaining with and without PK pre-treatment in the putamen/globus pallidus. PrP immunoreactivity practically disappears in PK-
treated section. H: PrP immunostaining in the cerebral cortex without PK pre-treatment showing PrP-positive punctate (synaptic-like) deposits
and large granular confluent deposits forming coarse plaque-like accumulations; I: A few PrP-immunoreactive granular deposits are seen in
sections after PK pre-treatment. A-C: haematoxylin and eosin; D: GAFP immunohistochemistry; E and F: CD68 immunostaining; G-I: PrP
immunohistochemistry.
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isoforms of 19, 16 and 6 kDa, which were more intense
in the cortex (parietal, frontal and temporal) and weaker
in the occipital cortex and putamen/globus pallidus. In
the thalamus region, two bands were detected, a more
intense one of 19 kDa and a weaker one of 16 kDa.
Finally, the cerebellum was the only region where a single
aglycosylated band of 19 kDa was observed (Figure 5C),
similar to that found in sCJD type 2. However, we cannot
rule out the possibility that this finding was the result of
the presence of a small amount of PrP
Sc and an underre-
presentation of the other bands, as observed in the thala-
mus, where a 16 kDa size band was only observed under
longer film exposure times.
Evaluation of sensitivity to PK digestion was achieved
by measuring the absorbance of PrP
Sc before and after
treatment with proteinase K using the IDEXX HerdChek
BSE Test. This technology is based on selective PrP
Sc
capture by a specific chemical polymer through polyionic
interactions in the presence of PrP
C from a brain homo-
genate sample. Absorbance values decrease with serial
dilutions, so it can be assumed that the quantity of PrP
Sc
is directly proportional to the absorbance. The goal of
this protocol was to perform relative quantification of
PrP
Sc without treatment with proteases. We consider
that the introduction of a digestion step could be useful
to easily evaluate the relativer e s i s t a n c et oP Kd i g e s t i o n .
The results showed that the absorbance values decreased
Figure 2 3F4 immunohistochemistry without and with proteinase K pre-treatment in the same regions of consecutive serial sections.
Parallel (A, B; C, D; and E, F) cortical regions pre-treated with proteinase K (B, D, F) show marked reduction of PrP immunoreactivity when
compared with serial sections without proteinase K pre-treatment (A, C, E). Different regions with variable amounts of total PrP were selected in
order to have a comprehensive idea of PrP sensitivity.
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multi-infarct encephalopat h y( M I E )a n ds C J DV V 2 ,t h e
signal detection was reduced in a 4.32% and 2.02%,
respectively, but the reductions were not statistically sig-
nificant. By contrast, samples from the proband and
sCJD MM1 showed a statistically significant (p < 0.005)
reduction of the signal in a 79.82% and 22.68%, respec-
tively. Absorbance values for MIE were below the cut-off,
at the same level as negative controls. The remaining
values were above the cut-off.
These differentiated levels of signal reduction are indica-
tive of three levels of resistance to PK digestion: high,
intermediate and low. A high resistance to PK digestion
would be represented by a low percentage of signal reduc-
tion, as observed for sCJD VV2. In this case, the reduction
of 2% in the signal would indicate that PK digestion would
only degrade a minimal fraction of PrP
Sc, thus suggesting
high resistance of the abnormal prion protein. Intermedi-
ate resistance would be represented by a slightly higher
percentage of signal reduction as observed in sCJD MM1,
in which 22% would point to a higher degradable fraction
of PrP
Sc than that observed in the previous case. This
would represent a protein type only slightly sensitive to
degradation with proteases, depending on the brain region.
Further investigations are being carried out in order to
elucidate whether this level of degradation is associated
with MM1 protein type or a phenomenon specific to this
subject. Finally, low resistance to PK digestion would be
represented by a high percentage of signal reduction, for
example the 79% observed in the proband, indicating that
a high fraction of PrP
Sc is degradable. This suggests the
existence of abnormal prion protein types extremely sus-
ceptible to protease digestion that might potentially be
overlooked by detection methods based on the character-
istic proteinase resistance of the pathologic prion protein.
Discussion
The present report describes a case of a novel human
disease with abnormal prion protein sensitive to pro-
tease and MV heterozygosity at polymorphic codon 129
Figure 3 3F4 and 1E4 immunohistochemistry in MV1 sCJD and the proband. 3F4 (A, B, E, F) and 1E4 (C, D, G, H) immunohistochemistry without
(A, C, E, G) and with (B, D, F, H) PK pre-treatment in the cerebellum of one case of sCJD MV1 with synaptic PrP deposition (A-D) and in the cerebellum
of the proband (E-H) show different patterns, when PK-treatment was performed. In the MV1 sCJD case, synaptic PrP deposition, as revealed with 3F4
and 1E4 antibodies, is observed in the molecular and granular layers of the cerebellum. PrP immunoreactivity is largely resistant to the treatment with
PK. Synaptic PrP immunoreactivity with the antibodies 3F4 and 1E4 is also found in the molecular and granular layer in the proband; however,
immunostaining is lost following incubation with PK. Notice that formic acid treatment did not seem to modify PK susceptibility.
Rodríguez-Martínez et al. BMC Neurology 2010, 10:99
http://www.biomedcentral.com/1471-2377/10/99
Page 5 of 10of the PRNP gene. A clinical picture of memory impair-
ment as a first symptom, followed by a rapid evolution
leading to an akinetic mutism in a 7-month course, was
compatible with sCJD [11]. However, post-mortem
examinations showed that neuropathological and bio-
chemical findings did not neatly conform to any of the
principal subtypes (MM/MV1, VV2, MV2K with kuru
type amyloid plaques; MM/MV2C with predominant
cortical pathology with confluent vacuoles and periva-
cuolar PrP staining; MM2T with prominent thalamic
pathology and atrophy; and VV1) [2,6,12].
In reference to biochemical and molecular findings, two
main striking biochemical features were observed: sensitiv-
ity to protease, resulting in an extremely weak PrP
Sc signal
in immunoblotting, and the multiband profile. Digestion
with decreasing concentrations of PK revealed a more PK-
sensitive protein than that observed in the control. Further
data supporting this was obtained by means of a metho-
dology based on the selective capture of PrP
Sc by a specific
chemical polymer. We first tested this technique in con-
trols in order to determine whether the anti-PrP specific
antibody could detect human PrP
Sc strains. After demon-
strating that the technique was applicable to human sam-
ples, we treated homogenates with PK prior to submitting
the samples (PK treated and untreated) to subsequent ana-
lyses. Data obtained this way showed that treatment with
proteases reduced the absorbance values proportionally to
PrP
Sc capture. This suggested a degradation of a fraction
of PrP
Sc molecules, which was minimal when the protein
type was highly resistant, intermediate when it was slightly
susceptible and variable depending on the brain region,
and maximal when it was highly susceptible. Furthermore,
treatment with milder PK digestion conditions and detec-
tion with Mab 3F4 showed a biochemical profile of five to
six bands of 28, 24, 21, 19, 16 and 6 kDa. Differential affi-
nity of antibodies 3F4 and 6H4 for PrP
Sc suggested a pro-
tein conformation on which epitope-recognising Mab 3F4
was more exposed than that of Mab 6H4. This protein
conformation appeared to be different from that of con-
trols since it did not show this unequal affinity for these
antibodies. Deglycosylation analysis revealed the presence
of up to three aglycosylated isoforms of 19, 16 and 6 kDa,
suggesting the coexistence of several PrP
Sc strains [13-15].
Recently, a novel human prion disease defined as a
protease-sensitive prionopathy (PSPr) was described in
11 cases. It is characterised by a distinct clinical and
neuropathological phenotype and by a PrP
Sc more sensi-
tive to PK, with a distinctive electrophoretic profile [10].
Our case showed some features compatible with this
novel disease [10] such as a family history of dementia,
prominent neuropsychiatric symptoms early in the evo-
lution and the absence of specific abnormalities in the
ancillary test such as EEG, 14-3-3 protein in CSF and
MRI. In contrast, our case had a short clinical course of
seven months (versus a median of 20 months in the
Gambetti et al. series) [10]. Regarding abnormal prion
protein, evaluation of the sensitivity to PK showed that
80% of the detectable abnormal PrP was PK sensitive,
with a ladder-like pattern on Western blot as seen in
other PSPr cases. However, it differed from them on the
earlier age at onset (74 years vs. upper range value 71),
the aforementioned clinical course, higher PrP
Sc iso-
forms (three aglycosylated isoforms of 19, 16 and 6 kDa,
versus two of 20 and 6 kDa) and MV genotype for
PRNP 129 polymorphism. Codon 129 appears to be the
most reliable factor to explain these dissimilarities, as
recently reported in other PSPr MM and MV cases
[16,17], and as observed in other human prion diseases
[11,18,19]. However, the existence of other unknown
factors cannot be discarded.
Regarding the neuropathological findings, the present
case differs from common subtypes of sCJD, including
those cases presenting with combined molecular sub-
types [12,20]. Main involvement of the putamen/globus
pallidus, thalamus and cerebral cortex with slight cerebel-
lar involvement, together with a lower band of 19 kDa, is
not common in pure MV cases [2,12]. Cases with MV1
show typical synaptic pattern of PrP immunostaining and
Figure 4 Immunoblot images under standard conditions.
A. 10% brain homogenate digested with 440 ug/ml PK final
concentration and incubated with Mab 3F4. M: Molecular weight
marker. 1-3: sCJD MM1 thalamus, frontal and temporal cortex,
respectively. 4-8: Occipital cortex, cerebellum, parietal cortex, frontal
cortex and temporal cortex of the patient, respectively. Film
exposure time: 5 minutes. Arrowheads indicate band position.
B. 10% brain homogenate digested with decreasing PK
concentration: 440 μg/ml (1, 4), 100 μg/ml (2, 5) and 50 μg/ml (3, 6)
and incubated with Mab 3F4. Temporal cortex of the patient (1-3)
and occipital cortex of a sCJD VV2 case (4-6).
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exhibit large numbers of kuru plaques [2,12]. Large con-
fluent vacuoles are common in MM2C but these also dif-
fer from the moderately large, non-confluent vacuoles
observed in the present case. Finally, PrP sensitive to PK,
as revealed in immunohistochemical sections, and further
validated by molecular studies, does not occur in com-
mon subtypes of sCJD [2,12].
Neuropathologically, this form differs from MV2 by
its lack of confluent vacuoles. It also differs from VV2
and MV2K in the absence of cerebellar plaque-like
deposits and kuru plaques, respectively. Mixed forms
MM/MV1+2C and MV2K+2C are also different for
analogous reasons. Finally, MM2T, characterised by
thalamo-olivary atrophy, and MM2V, characterised by
florid plaques, can be clearly distinguished from the
present form. The present case bears similarities to
M M / M V 1a n dV V 1a l t h o u g ht h eb a n dp a t t e r no fP r P
is obviously different. The original report stressed the
size of vacuoles as a distinctive feature, with the
vacuoles being larger than those currently seen in
Figure 5 Immunoblot images under modified methodology. A. Immunoblot with TeSeE® Western kit of patient occipital cortex (1) and sCJD
VV2 control (2) incubated with Mab Sha31. B. Immunoblot of TeSeE® digested and purified samples incubated with Mab 3F4 (upper) and 6H4
(lower). C. PNGase F digestion and detection with Mab 3F4. Film exposure time: 1 minute (upper) and 3 minutes (lower). M: molecular weight
marker. 1-8, respectively: occipital cortex, putamen/globus pallidus, cerebellum, parietal cortex, thalamus, frontal cortex, temporal cortex and sCJD
VV2 control.
Table 1 Results of the evaluation of proteinase K
digestion susceptibility
Case PK
treatment
Mean Std.
deviation
Signal
reduction (%)
P value
Proband No 1.189 0.698 79.82 <0.0001
Yes 0.240 0.140
sCJD
MM1
No 3.737 0.206 22.68 0.0041
Yes 2.890 1.076
MIE No 0.062 0.009 4.37 0.2740
Yes 0.059 0.004
sCJD
VV2
No 3.629 0.115 2.02 0.1133
Yes 3.556 0.152
Proband: The case reported here; sCJD MM1: Sporadic Creutzfeldt-Jakob
disease type 1 methionine homozygous at codon 129; sCJD VV2: Sporadic
Creutzfeldt-Jakob disease type 2 valine homozygous at codon 129; MIE: A
case of multi-infarct encephalopathy used as a negative control.
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were present in the cerebral cortex in the proband.
Sparser vacuoles, a bit larger in size, occurred in the
putamen/globus pallidus and thalamus, and they dif-
fered from the confluent microspongiosis usually seen
in MM/MV1 and VV1 cases. However, it is difficult to
draw fair conclusions on this point based on our parti-
cular case.
In summary, although clinical signs pointed to sCJD,
deposition of PrP sensitive to PK digestion and abnor-
mal prion protein with a ladder-like pattern indicated
that our case fitted better with a diagnosis of ‘protease-
sensitive prionopathy’. However, heterozygosis MV in
codon 129 of the prion protein gene suggested that it
might rather be a novel form of human disease with
abnormal prion protein sensitive to protease. From a
technical point of view, it should be noted that the use
of milder digestion conditions could provide interesting
information on the characteristics of ‘less frequent’
PrP
Sc strains involved in human TSEs. Additionally, the
application of new methods which allow the detection
of PrP
Sc without PK digestion could be of great value in
evaluating the level of resistance to PK of abnormal
prion protein types and the specific relation between
relative amounts of PrP
Sc and clinical and neuropatholo-
gical phenotypes.
Conclusions
A novel form of human disease with abnormal prion pro-
tein sensitive to protease was described. Although clinical
signs were compatible with sCJD, the molecular subtype
with the abnormal prion protein isoforms showing
enhanced protease sensitivity and a ladder-like pattern was
reminiscent of the ‘protease-sensitive prionopathy’.
Whether or not the genotypic difference from previously
reported PSPr cases influences the clinical and neuro-
pathological phenotype, as well as the prion protein con-
formation and its profile after digestion with proteinase K,
remains elusive. Nevertheless, this case established a sig-
nificant difference with that form of disease. The introduc-
tion of modifications in the analysis and detection
methodology, mainly focused on applying milder digestion
conditions, is necessary in order to detect these protei-
nase-sensitive proteins. This could also be complemented
by the use of analytical approaches that allow quantifica-
tion of PrP
Sc before and after treatment with PK. In this
manner, pathologic prion protein could be further charac-
terised using a new perspective that would help to study
the phenotypic variability of human prion diseases.
I ts h o u l dn o tb eo v e r l o o k e dt h a tt h em e t h o dp r e -
sented herein opens a way to more easily detecting
pathologic proteinase-susceptible prions associated with
other neurodegenerative diseases.
Methods
Clinical findings
The patient was subjected to standard clinical, electro-
encephalographic and MRI examinations.
Genetic findings
Analysis of PRNP was performed by standard sequen-
cing methods.
Neuropathology
Only the brain was removed at autopsy for neuropatho-
logical and biochemical examination. Following the
recommended safety guidelines, fresh samples from
seven areas (occipital, frontal, parietal and temporal cor-
tex, putamen/globus pallidus, thalamus and cerebellum)
were processed for neuropathological analyses. Selected
samples of the cerebral cortex, putamen/globus pallidus,
thalamus, cerebellum and brain stem fixed in 4% forma-
lin were treated with formic acid, and then post-fixed in
formalin and embedded in paraffin. De-waxed sections
were stained with haematoxylin and eosin and Klüver-
Barrera, or processed for immunohistochemistry, follow-
ing the En Vision+ system method, for glial fibrillary
acidic protein (GFAP), CD68 for microglia, hyper-
phosphorylated tau epitopes (antibody AT8), 3Rtau and
4Rtau, b-amyloid 1-40 and b-amyloid 1-42, a-synuclein,
aB-crystallin, ubiquitin, TDP-43, and prion protein
(antibodies 3F4 and 1E4) without and with PK pre-
treatment. Densitometry of immunohistochemical
sections not counterstained with haematoxylin was
analysed by using modified Total Laboratory v2.01 soft-
ware. Measurements were expressed as arbitrary units in
parallel PrP immunostained sections without and with
PK pre-treatment. The results were presented as a per-
centage of decreased immunoreactivity of PK-treated in
comparison with PK-untreated sections.
Biochemical analysis
Western blot
Eight brain regions corresponding to cortex (frontal,
temporal, occipital and parietal), cerebellum, caudate
nucleus, thalamus and putamen/globus pallidus were
analysed. 10% and 20% (w/v) brain homogenates were
prepared in lysis buffer [21]. The homogenates were
cleared by centrifugation at 2100 rpm and 4°C (Heraeus
Biofuge Fresco) for 5 minutes. Supernatants were trea-
ted with different final concentrations of proteinase K
(440 μg/ml, 100 μg/ml and 50 μg/ml) for 60 minutes at
37°C. The reaction was terminated by the addition of
Pefabloc SC (Roche-Diagnostics) to a final concentration
of 1 mM. An equal volume of 2× loading buffer (modi-
fied from [21]: 125 mM Tris-HCL pH 7; 4% SDS; 20%
glycerol; 0,02% bromophenol blue; 200 mM DTT) was
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minutes before electrophoresis on 16% SDS-Tris-glycine
gels (5% stacking) for 90 minutes at 150V. The gels
were electroblotted onto PVDF membrane (Immobilon-
P, Millipore) and blocked as described elsewhere [21].
After a short wash in PBST 1×, membranes were incu-
bated either with anti-PrP monoclonal antibody 3F4
(epitope 109-112: MKHM) (Sigma) (1:20.000) or 6H4
(epitope 144-152: DYEDRYYRE) (Prionics), diluted
1:5.000 for 1 h. Following a washing step in PBST 1×
for 45 min, membranes were incubated with an alkaline
phosphatase conjugated goat anti-mouse IgG antibody
(Sigma) diluted 1:10.000, and secondary against 6H4
(Prionics, dilution 1:5000) respectively in PBST 1× for
1 h at room temperature or at 4°C overnight. After a
washing step of 45 min in PBST 1× and equilibration in
200 mM Tris-HCl; 10 mM MgCl2, pH 9,8 [22] for
5 min, membranes were developed in chemiluminescent
substrate (CDP-STAR, Tropix) and visualised on
X-Omat AR film (Kodak).
In addition, samples were examined by TeSeE® Western
Blot (Bio-Rad) following the manufacturer’s recommenda-
tions. Briefly, 20% brain homogenate was incubated with
proteinase K and detergent solution for 10 min at 37°C
before addition of buffer B. After a short mixture, samples
w e r ec e n t r i f u g e da t1 5 0 0 0gf o r7m i n .T h ep e l l e tw a s
solubilised in 1× loading buffer (see above) by incubating
at 100°C for 5 min. Samples were then centrifuged at
15000 g for 15 min and supernatants were denatured at
100°C for 4 minutes before electrophoresis. Electrophor-
esis separation was performed as described above. Proteins
were transferred onto a PVDF membrane at 115V for 60
min and 4°C. Following transfer, the membrane was
soaked successively with PBS buffer, ethanol and distilled
water, and then saturated for 30 min with blocking solu-
tion. The membrane was incubated for 30 min at room
temperature with monoclonal antibody Sha31 against epi-
tope YEDRYYRE (145-152, huPrP), diluted 1:10 in PBST.
Following a washing step with PBST, the membrane was
incubated for 20 min with goat anti-mouse IgG antibody
conjugated to horseradish peroxidase diluted 1:10 in
PBST. Finally, membranes were developed in chemilumi-
nescent substrate (Western Blotting detection system,
ECL, Amersham) and visualised on film.
A combination of both protocols was also used. In
such cases, samples were digested and purified accord-
ing to TeSeE® Western Blot procedure and incubation
with monoclonal antibodies 3F4 and 6H4 was per-
formed as described above.
Deglycosilation analysis
In order to detect the non-glycosylated isoforms, sam-
ples (either proteinase K digested or purified with
TeSeE®) were subjected to PNGase F (New England
Biolabs) digestion overnight at 37°C and PrP
Sc was
recovered as described elsewhere [23].
Evaluation of sensitivity to PK digestion
For the evaluation of sensitivity to proteinase K diges-
tion the IDEXX HerdCheck BSE Test was performed
according to the manufacturer’s instructions [24] with
modifications. Tissue samples from eight brain regions
of four cases were analysed. These cases included a
s C J Dc o n t r o lM M 1 ,s C J Dc o n t r o lV V 2 ,M I Ea sp r i o n
disease negative control and the proband. In brief,
0.25 g of tissue was homogenised in a tissue-disruption
tube for 2 cycles of 23 seconds at 6500 rpm in a homo-
genizer. A fraction of brain homogenate was treated
with 100 μg/ml proteinase K (Sigma) for 1 hour at 37°C.
The reaction was stopped by adding 1 mM Pefabloc SC
(Roche). After this, 100 μlo fh o m o g e n i s e ds a m p l e s( P K
treated and untreated) were then diluted with 25 μlo f
working plate diluent, mixed by pippeting six times and
transferred (100 ul) to the BSE antigen capture enzyme
immunoassay plate. The plate was incubated at 34°C for
20 minutes at 200 rpm in a Thermo shaker PHMP-4
(Grant Instruments, Cambridge Ltd) in order to allow
the disease-associated conformer (PrP
Sc)t ob i n dt ot h e
immobilised ligand with high affinity. The plate was
washed three times with 1X Wash 1 in a Biotek ELx50™-
Microplate washer to remove unbound materials,
including PrP
C. The plate was then incubated with
100 μl of CC-conjugate for 25 minutes at 34°C and
washed five times with 1X Wash 2. Finally, the plate
was incubated with 100 μl horseradish peroxidase
(HRPO) substrate for 15 minutes at 34°C in the dark
prior to reading the optical density at 450 nm and
650 nm with a plate reader (Model SUNRISE, TECAN).
Colour development was related to the relative amounts
of PrP
Sc captured by the ligand immobilised in the
microtiter plate well. Negative controls, positive controls
and samples were analysed in duplicate. Results were
analysed with Magellan V6.3 software (Tecan Austria
GmbH). Calculations of negative controls means
(NCmean) were automatically made by the software
according to the formula (NCmean = (A1 (A450-A650)
+B1 (A450-A650))/2 where A1 and B1 are the plate wells
for negative control. The value corresponding to (A450-
A650) was calculated and applied as a correction factor
to the absorbance values of the samples. The statistical
significance of mean comparisons was checked with the
Student’s t-test for independent samples.
Consent
Written informed consent was obtained from the next
of kin of the patient for publication of this case report.
A copy of the written consent form is available for
review from the editor-in-chief of this journal.
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